Raymond James analyst Martin Auster lowered the firm’s price target on Dyne Therapeutics (DYN) to $31 from $37 and keeps an Outperform rating on the shares. Dyne’s DYNE-101 upsized registrational cohort is expected to complete enrollment in Q4, setting up a mid 2026 readout and late 2026 accelerated approval biologics license application filing, roughly on par with Avidity (RNA), the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $23 from $25 at RBC Capital
- Dyne Therapeutics: Promising Clinical Developments and Strategic Positioning Drive Buy Rating
- Dyne Therapeutics Advances in Neuromuscular Therapies
- Dyne Therapeutics reports Q2 EPS (97c), consensus (93c)
- Dyne Therapeutics expects cash to fund operations into Q3 of 2027